Cizzle Biotechnology Holdings PLC Total Voting Rights
30 Abril 2024 - 11:00AM
RNS Regulatory News
RNS Number : 5879M
Cizzle Biotechnology Holdings PLC
30 April 2024
30 April 2024
Cizzle Biotechnology Holdings
Plc
("Cizzle
Biotechnology" or the "Company")
Total Voting
Rights
Cizzle Biotechnology Holdings PLC
(LSE: CIZ), the UK based diagnostics developer, makes the following
announcement in accordance with Rule 5.6.1 of the Financial Conduct
Authority's ("FCA") Disclosure Guidance and Transparency
Rules.
As of 30 April 2024, the Company's
issued ordinary share capital consists of 396,391,773 ordinary
shares of 0.01 pence each, each with one voting right. The
Company holds no ordinary shares in Treasury. Therefore, the
Company's total number of ordinary shares and voting rights is
396,391,773 and this figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
Enquiries:
Cizzle Biotechnology Holdings plc
|
Via
IFC Advisory
|
Allan Syms (Executive
Chairman)
|
|
Allenby Capital Limited
|
+44(0) 20 33285656
|
John Depasquale
|
|
George Payne
|
|
Novum
Securities Limited
|
+44(0) 20 7399 9400
|
Colin Rowbury
Jon Bellis
|
|
IFC
Advisory Limited
|
+44(0) 20 3934 6630
|
Tim Metcalfe
|
|
Florence Chandler
|
|
About
Cizzle Biotechnology
Cizzle Biotechnology is developing a
blood test to facilitate the early detection of lung cancer based
on the ability to detect a stable plasma biomarker, a variant of
CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant has been shown to be highly correlated with early-stage
lung cancer. The Company's proprietary technology results
from the work of Professor Coverley and colleagues at the
University of York.
For more information please see
https://cizzlebiotechnology.com
You can also follow the Company
through its twitter account @CizzlePlc and on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVREAPLEDSELEEA
Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Oct 2024 a Oct 2024
Cizzle Biotechnology (LSE:CIZ)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024